Evaluation of Symbicort® Turbuhaler® (Budesonide/Formoterol) in Chronic Obstructive Pulmonary Disease (COPD)

AstraZeneca

Status: Completed

Conditions: Chronic Obstructive Pulmonary Disease

Study type: Observational

Funder types: Industry

Identifiers

NCT00837629

NIS-RSI-SYM-2006/1

Details and patient eligibility

About

This non-interventional study is to analyse the therapeutic effectiveness in patients with severe COPD following a generally accepted 12-week treatment period with Symbicort Turbuhaler, which could anyhow be shortened or extended at physician's discretion.

Enrollment: 743 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• non pregnant female
• COPD with persistent symptoms in spite of regular bronchodilator therapy
• Naive or fixed combination treated patients including patients already on Symbicort Turbuhaler

Exclusion criteria

• Hypersensitivity to budesonide, formoterol or inhaled lactose